Last reviewed · How we verify

NCT01255501

A First in Man Randomized Placebo Controlled Study of Single Ascending Intravenous Doses of NI-0701 in Healthy Volunteers

Completed Phase 1 Last updated 6 December 2010
What this trial tests

Phase 1 trial testing NI-0701 in Healthy Volunteers. Completed.

Quick facts

Lead sponsorLight Chain Bioscience - Novimmune SA
PhasePhase 1
StatusCompleted
Study typeINTERVENTIONAL
Sites1 location across United Kingdom

Drugs / interventions tested

Conditions studied

Sponsor

Light Chain Bioscience - Novimmune SA — full company profile →

Who can join

Adults 18 to 65, male only, with Healthy Volunteers. Healthy volunteers can join.

What's being measured

Primary outcomes are the specific endpoints the trial is designed to prove or disprove.

Sponsor's own description

The purpose of this study is to determine the safety, pharmacodynamic and pharmacokinetic profiles of a novel therapeutic drug when administered to healthy volunteers.

Publications & conference data

1 peer-reviewed publication reference this trial (live from Europe PMC):

  1. Targeting CCL5 in inflammation.
    Marques RE, Guabiraba R, Russo RC, Teixeira MM. · · 2013 · cited 285× · PMID 24090198 · DOI 10.1517/14728222.2013.837886

Verify or expand the search:

Other recruiting trials for Healthy Volunteers

Currently open trials in the same condition.

Other Light Chain Bioscience - Novimmune SA trials

Trials by the same sponsor.

Verify against primary sources

Data sources for this page

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT01255501.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing